Gynecologic Cancer Experts Review 2023 SGO Research and Treatment Updates

In Partnership With:

Partner | Cancer Centers | <b>Dana-Farber Cancer Institute</b>

Presenters from the 2023 SGO Annual Meeting share their insights on the treatment of patients with gynecologic cancers.

Welcome to OncLive On Air®! I’m your host today, Ashling Wahner.

OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with presenters from the 2023 SGO Annual Meeting, who shared their insights on the treatment of patients with gynecologic cancers.

Ursula A. Matulonis, MD, discussed final overall survival (OS) data from the phase 3 NOVA trial (NCT01847274) of niraparib (Zejula) in patients with recurrent ovarian cancer. Dr Matulonis is chief of the Division of Gynecologic Oncology and the Brock-Wilson Family Chair at Dana-Farber Cancer Institute and a professor of medicine at Harvard Medical School, both in Boston, Massachusetts.

Robert L. Coleman, MD, FACOG, FACS, discussed findings from an evaluation of the antitumor effects of treatment sequencing with mirvetuximab soravtansine-gynx (Elahere) in the phase 3 SORAYA trial (NCT04296890) in patients with folate receptor alpha–high, platinum-resistant ovarian cancer. Dr Coleman is the chief scientific officer of US Oncology Research in Houston, Texas.

Cara Mathews, MD, discussed 7-year OS data from the phase 3 SOLO-1 trial (NCT01844986) in patients with newly diagnosed, BRCA-mutated, advanced ovarian cancer who received maintenance olaparib (Lynparza). Dr Mathews is an associate professor of obstetrics and gynecology at Brown University and a gynecologic oncologist at Women & Infants Hospital, both in Providence, Rhode Island.

Ramez N. Eskander, MD, discussed findings from the phase 3 NRG GY018 trial (NCT03914612) of pembrolizumab (Keytruda) plus paclitaxel and carboplatin in patients with stage III, IVA, or IVB endometrial cancer. Dr Eskander is an assistant professor of obstetrics, gynecology, and reproductive sciences at the University of California San Diego Moores Cancer Center.

Finally, Mansoor Raza Mirza, MD, discussed findings from the interim analysis of the phase 3 RUBY trial (NCT03981796) of dostarlimab-gxly (Jemperli) plus chemotherapy in patients with primary advanced or recurrent endometrial cancer. Dr Mirza is chief oncologist in the Department of Oncology at Rigshospitalet, Copenhagen University Hospital in Denmark.

___

That’s all we have for today! Thank you for listening to this episode of OncLive On Air®. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air®.

*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.